CytoLynx Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Joint Venture

  • Financing Rounds
  • 1

CytoLynx Therapeutics General Information

Description

Operator of a research and commercialization platform intended to bring disruptive medicines to Greater China and worldwide. The company focuses on promoting a variety of NK therapies through product development.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Room A1302, 13th Floor, Building 3
  • No.702 Zhongke Road, China (Shanghai) Pilot Free Trade Zone
  • Shanghai
  • China
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • Room A1302, 13th Floor, Building 3
  • No.702 Zhongke Road, China (Shanghai) Pilot Free Trade Zone
  • Shanghai
  • China

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CytoLynx Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CytoLynx Therapeutics‘s full profile, request access.

Request a free trial

CytoLynx Therapeutics Patents

CytoLynx Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4023673-A1 Humanized monoclonal antibody targeting bcma and having human monkey cross-reactivity Pending 10-Oct-2019
EP-4023673-A4 Humanized monoclonal antibody targeting bcma and having human monkey cross-reactivity Pending 10-Oct-2019
US-12479922-B2 Humanized monoclonal antibody targeting bcma and having human monkey cross-reactivity Active 10-Oct-2019
US-20240052048-A1 Humanized monoclonal antibody targeting bcma and having human monkey cross-reactivity Active 10-Oct-2019 C07K16/2878

CytoLynx Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CytoLynx Therapeutics‘s full profile, request access.

Request a free trial

CytoLynx Therapeutics FAQs

  • When was CytoLynx Therapeutics founded?

    CytoLynx Therapeutics was founded in 2021.

  • Where is CytoLynx Therapeutics headquartered?

    CytoLynx Therapeutics is headquartered in Shanghai, China.

  • What industry is CytoLynx Therapeutics in?

    CytoLynx Therapeutics’s primary industry is Biotechnology.

  • Is CytoLynx Therapeutics a private or public company?

    CytoLynx Therapeutics is a Private company.

  • What is CytoLynx Therapeutics’s current revenue?

    The current revenue for CytoLynx Therapeutics is .

  • Who are CytoLynx Therapeutics’s investors?

    BioTrack Capital, Cytovia Therapeutics, Everbright ReinFore, Hangzhou Tigermed Consulting Company, and TF Capital are 5 of 6 investors who have invested in CytoLynx Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process